Ticker Details
CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date:	October 19, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.29B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.61 | 2.80%
Avg Daily Range (30 D):	$1.34 | 2.59%
Avg Daily Range (90 D):	$1.46 | 2.74%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.56M
Avg Daily Volume (90 D):	1.68M

Trade Size
Avg Trade Size (Sh.):	62
Avg Trade Size (Sh.) (30 D):	50
Avg Trade Size (Sh.) (90 D):	52

Institutional Trades
Total Institutional Trades:	6,507
Avg Institutional Trade:	$2.95M
Avg Institutional Trade (30 D):	$2.44M
Avg Institutional Trade (90 D):	$2.64M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.69M
Avg Closing Trade (30 D):	$7.5M
Avg Closing Trade (90 D):	$8.19M
Avg Closing Volume:	90.75K

News

May 6, 2026 @ 7:30 AM Is This Millionaire-Maker Biotech Stock a Buy Righ... Source: Prosper Junior Bakiny

Apr 30, 2026 @ 10:10 AM Want to Build Real Wealth in Healthcare? These Sto... Source: Adria Cimino

Apr 30, 2026 @ 9:10 AM What's the Next Big Thing After GLP-1 Drugs? CRISP... Source: Adria Cimino

Apr 30, 2026 @ 7:10 AM Should You Forget This High-Yield Pharma Stock and... Source: Adria Cimino

Apr 27, 2026 @ 4:09 PM S&P 500 Holds Near Highs Despite Oil Shock and Wea... Source: Itai Smidt

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-6.2	$-1.28	$-1.35
Diluted EPS	$-6.2	$-1.28	$-1.35
Revenue	$4.1M	$1.46M	$.86M
Gross Profit
Net Income / Loss	$-568.53M	$-122.93M	$-130.61M
Operating Income / Loss	$-646.4M	$-130.25M	$-154.76M
Cost of Revenue
Net Cash Flow	$184.59M	$72.27M	$61.06M
PE Ratio